Faron Pharmaceuticals Share News (FARN)

Faron Pharmaceuticals Information

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes

Get Live Data

46.00 -1.40 (-2.95%)

Bid:

45.00

Ask:

47.00

Spread: 2.00 (4.444%)

Market Cap: £91.78m

Last checked at -

Intraday Faron Pharmaceuticals Share Chart

REMOVE ADS

Faron Pharmaceuticals Notes Study Supporting Clevegen Programme

Mon, 30th Nov 2015 09:35

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.

Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.

"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.

Shares in Faron were trading flat at 275.00 pence on Monday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance